EMA
safety_alert
· 2007-02-07
Public statement: Vasovist and nephrogenic systemic fibrosis (NSF)
Summary
EMA public statement regarding the contrast agent Vasovist and the risk of nephrogenic systemic fibrosis (NSF), highlighting safety considerations and recommen…
Upgrade for the full analysis, importance score, and drug timeline.